Loading…
Loading…
EQUITY / NASDAQ · XNCM
Aldeyra Therapeutics Inc
01 / RESEARCH
8 financial reports are available for research.
Start research ↗1.23 USD
Observed: 09/30/2026 · tickerlayer · Historical end-of-day close
Powered by TickerLayer
09/30/2026 · 1.23 USD · Volume 1,648,490
252 actual observations · Latest bar: 2026-09-30 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | Prior year | Change |
|---|---|---|---|
| Net income | -5,450,273 USD | — | — |
| Operating profit | -5,850,507 USD | — | — |
| Total assets | 47,540,559 USD | — | — |
| Total equity | 37,885,303 USD | — | — |
| Total liabilities | 9,655,256 USD | — | — |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 2ConsolidatedUnits · USD | 2026 / Quarter 2ConsolidatedUnits · USD | 2026 / Quarter 2ConsolidatedUnits · USD | 2026 / Quarter 1ConsolidatedUnits · USD | 2025 / Quarter 2ConsolidatedUnits · USD | 2025 / Year endConsolidatedUnits · USD | 2025 / Quarter 3ConsolidatedUnits · USD | 2025 / Quarter 3ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Net incomeIncome statement | -5,450,273 USD | -8,902,892 USD | — | -3,452,619 USD | — | -33,846,661 USD | -7,688,341 USD | -27,385,154 USD |
| Operating profitIncome statement | -5,850,507 USD | -9,397,425 USD | — | -3,546,918 USD | — | -35,265,206 USD | -8,001,132 USD | -28,597,323 USD |
| Total assetsBalance sheet | 47,540,559 USD | — | — | 66,483,081 USD | 72,059,317 USD | 72,059,317 USD | 77,801,012 USD | — |
| Total equityBalance sheet | 37,885,303 USD | — | 42,156,792 USD | 42,156,792 USD | 44,250,390 USD | 44,250,390 USD | 49,244,543 USD | — |
| Total liabilitiesBalance sheet | 9,655,256 USD | — | — | 24,326,289 USD | 27,808,927 USD | 27,808,927 USD | 28,556,469 USD | — |
| Financing cash flowCash flow statement | — | -15,228,860 USD | — | 71,140 USD | — | 1,123,556 USD | — | 1,123,556 USD |
| Investing cash flowCash flow statement | — | -23,097 USD | — | 0 USD | — | 47,736,288 USD | — | 31,736,288 USD |
| Operating cash flowCash flow statement | — | -9,699,511 USD | — | -5,110,089 USD | — | -33,345,682 USD | — | -28,046,337 USD |
| Cash and cash equivalentsBalance sheet | — | — | — | — | — | 70,041,254 USD | 59,340,599 USD | — |
| Report source | Open report ↗ Published: 08/06/2026 | Open report ↗ Published: 08/06/2026 | Open report ↗ Published: 08/06/2026 | Open report ↗ Published: 05/07/2026 | Open report ↗ Published: 08/06/2026 | Open report ↗ Published: 02/27/2026 | Open report ↗ Published: 11/05/2025 | Open report ↗ Published: 11/05/2025 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.